MedTrace Logo

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT03531060 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-05-21

No results posted yet for this study

Summary

This is a Phase 1b study investigating the safety and tolerability of IRl790 as adjunct therapy in patients with Parkinson disease. IRL790/placebo is taken for 28 days.

Conditions

  • Parkinson Disease

Interventions

DRUG

IRL790

IRL790 capsule 10 mg

DRUG

Placebo

Placebo capsule

Sponsors & Collaborators

  • Integrative Research Laboratories AB

    lead INDUSTRY

Principal Investigators

  • Per Svenningsson, MD, PhD · Karolinska Institutet, Stockholm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-08
Primary Completion
2017-04-12
Completion
2017-04-12

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03531060 on ClinicalTrials.gov